Royal Bank of Canada’s Sarepta Therapeutics SRPT Stock Holding History

Royal Bank of Canada’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,800	Closed	-$232K	–	7659
2025 Q4	$232K	Hold	10,800	–	–	﹤0.01%	4668
2025 Q3	$208K	Hold	10,800	–	–	﹤0.01%	5077
2025 Q2	$185K	Sell	10,800 -23,500	-69%	-$1M	﹤0.01%	5224
2025 Q1	$2.19M	Buy	+34,300	New	+$3.61M	﹤0.01%	2879
2019 Q3	–	Sell	-600	Closed	-$91K	–	7079
2019 Q2	$91K	Sell	600 -500	-45%	-$60.8K	﹤0.01%	4934
2019 Q1	$131K	Buy	+1,100	New	+$141K	﹤0.01%	4608
2014 Q2	–	Sell	-20,000	Closed	-$481K	–	6119
2014 Q1	$481K	Buy	+20,000	New	+$510K	﹤0.01%	3377
2013 Q3	–	Sell	-28,000	Closed	-$1.06M	–	6244
2013 Q2	$1.06M	Buy	+28,000	New	+$1M	﹤0.01%	2517

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada's SRPT Position: Q1 2026 in Review

Royal Bank of Canada increased its Sarepta Therapeutics (SRPT) stake by 7.7% in Q1 2026, buying an estimated $308K and bringing the position to 222,850 shares worth $4.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2440.

Royal Bank of Canada first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $78.5M in Q4 2023. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Royal Bank of Canada held 222,850 shares of Sarepta Therapeutics worth $4.85M as of Q1 2026.
Royal Bank of Canada bought 15,888 Sarepta Therapeutics shares in Q1 2026, an estimated $308K.
Sarepta Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2440 holding.
Royal Bank of Canada first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's Sarepta Therapeutics position peaked at $78.5M in Q4 2023.
341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.